ClinicalTrials.gg
Active, not recruitingNCT07662122Updated Nov 12, 2026

A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight

A Phase 2 interventional study of BI 3034701 and Placebo matching BI 3034701 in Obesity and Overweight, sponsored by Boehringer Ingelheim. Active, not recruiting at 55 sites in 6 countries. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Updated Nov 12, 2026Enrollment updatedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
345
Allocation
Randomized
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies in Obesity by Boehringer Ingelheim — 5 open to participants now, 11 under way, 3 of them phase 3. Obesity · Boehringer Ingelheim.

Enrollment
9th of 31
345 · median 88
Started
2026
with 9 others
Phase 2
4 of 32
none open now
Primary completion
2027-06
later than 5 of 10 live
Registered
25th of 32
by date

Among the 32 studies in Obesity by Boehringer Ingelheim, this one is the 9th largest by enrollment of the 31 interventional ones that give a count, is one of 10 that started in 2026, is one of 4 in phase 2, reaches primary completion later than 5 of the 10 other live ones, and was the 25th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

5 of the 32 studies in Obesity by Boehringer Ingelheim are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Obesity by Boehringer Ingelheim, or all of them as a file.
02

Study summary

This study is open to adults between 18 and 74 years of age and who have a body mass index (BMI) of 30 kg/m2 or more, or a BMI of 27 kg/m2 or more and at least 1 health problem related to their weight. People who have previously not managed to lose weight by changing their diet can participate. People with type 2 diabetes cannot take part in this study.

The purpose of this study is to find out whether a medicine called BI 3034701 helps people living with obesity or overweight to lose weight. This study has 7 groups of participants. Groups 1 to 6 get different doses of BI 3034701; Group 7 gets placebo. Placebo looks like BI 3034701 but does not contain any medicine. Every participant has more than an 80% chance of getting BI 3034701. Participants receive 2 injections of BI 3034701 or placebo under their skin for 42 weeks. In addition to the study medicine, all participants receive counselling to make changes to their diet and to exercise regularly.

Participants are in the study for about 10 months. During this time, they visit the study site 15 times. The study doctors regularly measure the participants' body weight and take necessary laboratory tests. Participants also answer questions about their well-being and note their food intake and physical activity in diaries. The results will be compared between groups of participants to see whether the treatment works. The study doctors also regularly check participants' health and take note of any unwanted effects.

03

Conditions studied

  • Obesity
  • Overweight
04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, age ≥18 to \<75 years at the time of signing , and at least the legal age of consent in countries where it is >18 years
  2. (BMI) ≥30 kg/m² at screening, OR BMI ≥27 kg/m² at screening with the presence of at least 1 weight-related complication.
  3. History of at least one self-reported unsuccessful dietary effort to lose body weight
  4. Signed and dated written informed consent in accordance with International Conference on Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial. Persons must be capable of giving informed consent independently
  5. Women of (WOCBP) must be ready and able to use highly effective methods of per International Conference on Harmonisation (ICH) M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria and instructions on the duration of their use will be provided in the participant information sheet and in protocol.
  6. In the investigator's opinion, participants are well-motivated, capable, and willing to: Sign the informed consent form (ICF); Learn how to self-inject the medicinal product (IMP)(s) in the abdomen as required for this protocol (persons with physical limitations who are not able to perform the injections must have the assistance of an individual trained to inject the IMP(s)) OR Inject the IMP or accept injection from a designated person; Follow study procedures for the duration of the study, including, but not limited to: follow lifestyle advice (for example, dietary restrictions and physical activity plan), maintain diaries, complete required questionnaires, and handle the IMP(s) as described in the instructions for use (IFU)

Exclusion criteria

Exclusion criteria:

  1. Body weight increase or decrease (self-reported) of greater than 5% in the 3 months prior to screening
  2. Treatment with anti-obesity medication and/or body weight change-inducing medication within 3 months before screening
  3. Prior surgery of the gastrointestinal (GI) tract that could interfere with body weight including minimally invasive/endoscopic bariatric devices and any bariatric or metabolic surgery involving resection, sleeve gastrectomy, or bypass procedures (e.g. Roux-en-Y, one-anastomosis gastric bypass, duodenal-jejunal bypass sleeve), regardless of whether the device or bypass was removed. The following are allowed: (1) liposuction and/or abdominoplasty, if performed >1 year before screening, (2) lap banding, if the band has been removed >1 year before screening, (3) intragastric balloon, if the balloon has been removed >1 year before screening
  4. Have obesity induced by other endocrinologic disorders (for example, Cushing Syndrome) or diagnosed monogenetic or syndromic forms of obesity (for example, melanocortin 4 receptor deficiency, leptin deficiency, or Prader Willi Syndrome)
  5. A (HbA1c) ≥6.5% (≥48 mmol/mol) as measured by the central laboratory at screening
  6. History of type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) or treatment with glucose-lowering agent starting within 3 months before screening
  7. Use of glucagon-like-peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), glucagon receptor (GCGR) or neuropeptide Y receptor 2 (NPY2R) agonists (or the combinations thereof) within 3 months before screening
  8. Answered "yes" to any of the suicide-related behaviours (actual attempt, interrupted attempt, aborted attempt, preparatory act or behaviour) or to the non-suicidal self-injurious behaviour question on the "Suicidal Behaviour" section of the Columbia-Suicide Severity Rating Scale (C-SSRS) related to the past 2 years before screening visit up to and including the randomisation visit Further exclusion criteria apply.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
345 participants (actual)

Study arms

  • Experimental
    BI 3034701 treatment group 1

    Drug: BI 3034701

  • Experimental
    BI 3034701 treatment group 2

    Drug: BI 3034701

  • Experimental
    BI 3034701 treatment group 3

    Drug: BI 3034701

  • Experimental
    BI 3034701 treatment group 4

    Drug: BI 3034701

  • Experimental
    BI 3034701 treatment group 5

    Drug: BI 3034701

  • Experimental
    BI 3034701 treatment group 6

    Drug: BI 3034701

  • Placebo comparator
    Placebo

    Drug: Placebo matching BI 3034701

Interventions

  • BI 3034701

  • DrugPlacebo matching BI 3034701

    Placebo matching BI 3034701

06

What researchers measure

Primary outcomes

  1. Percentage change in body weight from baseline at Week 42 [%]

    Time frame: Baseline and at Week 42.

Secondary outcomes

  1. Achievement of weight loss of ≥5% of baseline weight at Week 42

    Time frame: Baseline and at Week 42.

  2. Achievement of weight loss of ≥10% of baseline weight at Week 42

    Time frame: Baseline and at Week 42.

  3. Achievement of weight loss of ≥15% of baseline weight at Week 42

    Time frame: Baseline and at Week 42.

  4. Achievement of weight loss of ≥20% of baseline weight at Week 42

    Time frame: Baseline and at Week 42.

  5. Absolute change from baseline at Week 42 in body weight [kg]

    Time frame: Baseline and at Week 42.

  6. Absolute change from baseline at Week 42 in waist circumference [cm]

    Time frame: Baseline and at Week 42.

  7. Absolute change from baseline at Week 42 in waist-to-height ratio (WHtR) [dimensionless ratio]

    Time frame: Baseline and at Week 42.

  8. Absolute change from baseline at Week 42 in systolic blood pressure (SBP) [mmHg]

    Time frame: Baseline and at Week 42.

  9. Absolute change from baseline at Week 42 in diastolic blood pressure (DBP) [mmHg]

    Time frame: Baseline and at Week 42.

07

Study locations

55 sites
08

References and documents

Related links

Individual participant data

Plan to share: Yes — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

Access criteria: For study documents -upon signing of a 'Document Sharing Agreement'. For study data -1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.clinicalstudies.boehringer-ingelheim.com

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2027, 11 months after the start.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's planned 11 months is close to that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 29, 2026: primary completion Aug 2027 → Jun 2027 and completion Aug 2027 → Jul 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2026
First posted
Jun 23, 2026
StartActual
Jun 30, 2026
Primary completionEst.
Jun 26, 2027was Aug 2027
CompletionEst.
Jul 10, 2027was Aug 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added, 2 sites removed
Show 3 added (2 United States, 1 Australia)
  • Texas Diabetes and Endocrinology - Central Austin · Austin, United States
  • South Texas Research Institute - Edinburg · Edinburg, United States
  • Royal Prince Alfred Hospital · Camperdown, Australia
Show 2 removed
  • Texas Diabetes and Endocrinology · Austin, United States
  • South Texas Research Institute-Edinburg-67012 · Edinburg, United States
across 2 updates, Sep 29, 2026 – Nov 12, 2026
Primary completion
Aug 4, 2027→Jun 26, 2027
Sep 29, 2026
Study completion
Aug 18, 2027→Jul 10, 2027
Sep 29, 2026
Enrollment
342→345
Nov 12, 2026
Show all 3 updates
  1. Nov 12, 2026
    2 sites added, 1 site removed
    Show 2 added (1 United States, 1 Australia)
    • South Texas Research Institute - Edinburg · Edinburg, United States
    • Royal Prince Alfred Hospital · Camperdown, Australia
    Show 1 removed
    • South Texas Research Institute-Edinburg-67012 · Edinburg, United States
    Enrollment 344→345
    + 1 other change: verification date
  2. Oct 13, 2026
    Minor edits only
    + 1 other change: verification date
  3. Sep 29, 2026
    1 site added, 1 site removed
    Show site
    • Texas Diabetes and Endocrinology - Central Austin · Austin, United States
    Show 1 removed
    • Texas Diabetes and Endocrinology · Austin, United States
    Primary completion Aug 4, 2027→Jun 26, 2027
    Study completion Aug 18, 2027→Jul 10, 2027
    Enrollment 342→344

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07662122
Responsible party
Sponsor
First posted
Jun 23, 2026
Start date
Jun 30, 2026
Primary completion
Jun 26, 2027 (estimated)
Completion
Jul 10, 2027 (estimated)
Last update
Nov 12, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BI 3034701

Start the discussion